구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab) Bristol Myers Squibb·Lung Cancer 4 trials |
|---|---|
Overview Program | ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Lung Cancer |
Overview Indication | Liver Cancer; Antibody |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , their use must be carefully considered in patients with allografts and concomitant cancer |
PK/PD Experiment | PD |
Toxicology Major finding | A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases.. Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanom… |
Clinical Safety signal | A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases.. Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanom… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab) Bristol Myers Squibb·Lung Cancer 4 trials |
|---|---|
Overview Program | ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Lung Cancer |
Overview Indication | Liver Cancer; Antibody |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , their use must be carefully considered in patients with allografts and concomitant cancer |
PK/PD Experiment | PD |
Toxicology Major finding | A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases.. Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanom… |
Clinical Safety signal | A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases.. Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in advanced malignancies but are frequently associated with immune-related adverse events. Vitiligo, a distinctive cutaneous immune-related adverse event, correlates with favorable prognosis in melanom… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교